symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CELC,8.7,0.610784,58559,192183870,0,7.5-14.402,-1.8,Celcuity Inc.,USD,0001603454,US15102K1007,15102K100,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.celcuity.com,"Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.",Mr. Brian F. Sullivan,Healthcare,US,45,763 392 0767,16305â€“36th Avenue North,Minneapolis,MN,55446,7.4942,17.9042,https://financialmodelingprep.com/image-stock/CELC.png,2017-09-20,True,False,True,False,False
